US Patent

US8163902 — Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Method of Use · Assigned to Rigel Pharmaceuticals Inc · Expires 2026-06-17 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects prodrugs of biologically active 2,4-pyrimidinediamine compounds and their uses, including compositions and methods for synthesizing them.

USPTO Abstract

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2294`	—	fostamatinib-disodium
`U-2294`	—	fostamatinib-disodium

Patent Metadata

Patent number: US8163902
Jurisdiction: US
Classification: Method of Use
Expires: 2026-06-17
Drug substance claim: Yes
Drug product claim: No
Assignee: Rigel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.